Cargando…
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
SIMPLE SUMMARY: The approach to relapsed and refractory classical Hodgkin lymphoma is rapidly evolving. Over the past five years, we have seen the arrival of novel immunotherapies with impressive clinical response rates. These agents are actively being investigated earlier in the sequence of therapi...
Autores principales: | Voorhees, Timothy J, Beaven, Anne W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601361/ https://www.ncbi.nlm.nih.gov/pubmed/33050054 http://dx.doi.org/10.3390/cancers12102887 |
Ejemplares similares
-
Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021) -
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
por: Randall, Michael P., et al.
Publicado: (2023) -
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015) -
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
por: Hanel, Walter, et al.
Publicado: (2023) -
Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib
por: Brander, Danielle M, et al.
Publicado: (2012)